Hepatology

Article	Citations
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	1799
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	1579
Reply	1431
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	908
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	461
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	385
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	297
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	224
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	213
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	212
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	208
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	208
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	185
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	179
Efficacy and safety of infliximab in patients with autoimmune hepatitis	177
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	175
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	169
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	169
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	162
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	159
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	143
Cover Image	141
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	140
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	131
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	130

Alan Hofmann (1931‐2021): A career well spent understanding bile acids	126
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	125
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	124
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	122
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	122
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	122
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	117
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	114
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	110
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	109
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	109
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	108
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	105
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	105
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	104
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	104
Late-Breaking Abstracts	103
Access to technology to support telehealth in areas without specialty care for liver disease	102
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	101
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	101
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	99
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	99
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	99
Regulatory role and translational potential of CCL11 in liver fibrosis	98
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	98
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	94
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	91
	89
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	89
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	86
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	86
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	85
	85
Reply	84
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	84
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	84
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	84
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	83
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	83
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	82
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	81
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	80
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	80
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	80
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	79
Metabolic dysfunction-associated steatotic liver disease and the heart	79
Much more needed in natural history of Alagille syndrome	78
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	78
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	76
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	76

Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	75
Genes that fit just right: Unzipping the genome of fatty liver disease	75
Therapeutic manipulation of the microbiome in liver disease	75
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	74
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	73
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	73
Immunobiology of primary sclerosing cholangitis	73
NAFLD‐related hepatocellular carcinoma: The growing challenge	73
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	72
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	72
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	70
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	69
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	69
The international quest for the imaging diagnosis of liver cancer	69
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	68
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	68
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	68
In vivo imaging of calcium dynamics in zebrafish hepatocytes	68
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	67
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	67
Letter to the Editor: Overlooking the important factor: Hypoxia	66
Hepatology Highlights	65
Fontan‐associated liver disease	65
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?	65
To Be or Not to Be: The Quest for Patatin‐Like Phospholipase Domain Containing 3 p.I148M Function	65
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	65
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	64
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	64
The digital determinants of liver disease	62
Letter to the editor	62
Letter to the Editor: Proton Pump Inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?	62
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	62
With Alcohol as the Fuel, COVID Is the Match: Liver Transplantation for Alcohol‐Associated Liver Disease Is Increasing in the United States	62
Healthy peribiliary glands are necessary for successful liver transplantation	61
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	61
Erratum	61
Instructions to Authors	61
A strategy of vascular‐targeted therapy for liver fibrosis	60
Reply: The CRAPT-M score: Robust enough for clinical practice?	60
Endpoints and New Options for Treatment of Chronic Hepatitis D	60
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	59
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	59
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	59
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	59
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	59
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	58
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	58
The clot and the complicated consult	58
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	58
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	57
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	57
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	57
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	56
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	56
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	56
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	56
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and Immunotherapy response	55
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	55
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	55
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	54
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	54
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	53
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	53
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	53
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	53
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	52
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	52
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	52
Oral Abstracts	52
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	52
Hepatology Highlights	52
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	51
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	51
Reply	51
Reply	51
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	50
Manuscript best practices: Takeaways from a community conversation	50
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	50
Reply	50
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	50

Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	49
Reply	49
Reply	49
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	49
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	48
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	48
REPLY:	47
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	47
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	47
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	47
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	47
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	46
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	46
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	46
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	46
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	46
Pathway to global elimination of hepatitis B: HBV cure is just the first step	46
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	45
Masthead	45
Prognostic significance of mild ascites in patients with cirrhosis	45
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	45
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	45
Future directions in acute liver failure	45
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	44
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	44
Predicting liver outcomes with biomarker monitoring in MASLD	44
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	44
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	44
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	44
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	43
Intrahepatic cholangiocarcinoma PANoptosidy	43
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	43
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	43
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	43
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	43
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	43
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	42
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	42
Letter to the editor: HuR in liver homeostasis	42
Imaging for better responses to immunotherapy in hepatocellular carcinoma	42
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	42
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	41
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	41
Telehealth interventions in patients with chronic liver diseases: A systematic review	41
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	41
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	40
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	40
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	40
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	40
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	40
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	39
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	39
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	39
Cover Image	39
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	39
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	39
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Masthead	38
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	38
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	38
Table of contents	38
Reply	38
Presenting the new incoming editorial team for hepatology: Team members and perspectives	38
Table of contents	38
Reply	38
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	38
Cover Image	38
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease	37
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	37
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	37
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	37
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	37
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	37
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	37
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	37
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma	37
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	37
The evolving role of liver sinusoidal endothelial cells in liver health and disease	37
Category Index	36
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	36
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	36
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	36
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	36
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	36
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	36
A global action agenda for turning the tide on fatty liver disease	36
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	36
Abdominal surgery in patients with chronic noncirrhotic extrahepatic portal vein obstruction: A multicenter retrospective study	35
Letter to the editor: Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	35
AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension	35
Category Index	35
Circulating HBV RNA: From biology to clinical applications	35
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	35